Lucid Diagnostics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.1%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.24next fiscal year
Monitoring Framework
Key Performance Indicators
EsoGuard Esophageal DNA Tests Processed Quarterly3.2K
EsoGuard Recognized Revenue Quarterly1.3M
Watch Items
- Medicare Local Coverage Determination (LCD) ReconsiderationTrigger: Final positive coverage decision from CMS/MolDXAction: Accelerate commercial sales force deployment and target Medicare-eligible populations to drive high-margin test volume.
- Cash Runway and Capital SufficiencyTrigger: Cash balance falling below $15 millionAction: Evaluate additional non-dilutive financing, strategic partnerships, or parent company (PAVmed) support to extend runway.
Research as of 19 Jun 2026